The European Commission is due to decide next month whether to go ahead with legislation that would allow generics and biosimilar companies in Europe to manufacture stocks of their versions of medicines that are still protected by EU supplementary protection certificates (SPCs), provided the products are destined for markets outside the EU.
Marc Alexander Mahl, president of the generic and biosimilars industry body, Medicines for Europe, said there was a need to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?